Key Products

Technologies

PacBio offers three highly differentiated core technologies focused on accuracy, quality, and completeness:

1. HIFI SEQUENCING

Single-molecule sequencing provides a combination of read lengths up to 25 Kb, remarkable read accuracy of 99.9%, and 5-base sequencing (A, T, G, C + 5mC)

2. SEQUENCING BY BINDING (SBB)

SBB technology brings unmatched accuracy — even in regions of the genome prone to sequencing errors

3. NANOBIND

Sample extraction technology protects DNA from shearing to generate longer fragments with less damage across a broader range of sample types than any other technology

Sequencing Systems

Building on years of cutting-edge research and development, their systems enable researchers to make discoveries that will change the world. Explore the unparalleled accuracy of our long-read and short-read sequencing systems.

1. REVIO SYSTEM

Industry-leading accuracy with HiFi sequencing for complete views of genomes, epigenomes, and transcriptomes.

2. ONSO SYSTEM

Greater level of sensitivity to detect rare variants

3. SEQUEL IIe SYSTEM

Long, accurate HiFi reads with DNA methylation direct from the instrument in every run. Supports a wide range of applications – targeted sequencing, RNA sequencing, and whole-genome sequencing

Sequencing Methods

Single Molecule, Real-Time (SMRT) sequencing supports numerous sequencing applications, bringing new levels of depth and quality to genetic data. Whether you are performing targeted or whole genome sequencing, studying complex populations, or honing in on isoforms or epigenetic modifications, you can elevate your research and gain a competitive edge with SMRT sequencing.

1. WHOLE GENOME SEQUENCING

Long-read SMRT sequencing provides a comprehensive view of the genetic composition of microbes, humans, plants, and animals.

2. TARGETED SEQUENCING

Long-read SMRT sequencing produces in-depth views of genetic variation in human disease, plants, animals, microbes, and infectious disease.

3. RNA SEQUENCING

PacBio highly accurate long-read sequencing offers enhanced RNA sequencing capabilities, producing full-length transcripts without the need for assembly.

Data Analysis

Unlock the potential of PacBio Single Molecule, Real-Time (SMRT) sequencing using their portfolio of tools to analyze, visualize and annotate your sequencing data.

Software Downloads

PacBio’s open-source SMRT Analysis software suite is designed for use with Single Molecule, Real-Time (SMRT) sequencing data. You can analyze, visualize, and manage your data through an intuitive GUI or command-line interface. You can also integrate SMRT Analysis in your existing data workflow through the extensive set of APIs provided.

Key Executives

Christian Henry, President & Chief Executive Officer

Christian Henry has more than two decades of experience with growing companies in the life sciences industry. From 2005 through January 2017, Mr. Henry was an executive at Illumina, Inc., where he served in a number of different roles including Chief Financial Officer, Chief Commercial Officer and General Manager of the Life Sciences Business. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, a publicly traded online ticket provider, which was acquired by Major League Baseball Advanced Media, LP. Mr. Henry also served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a BA in biochemistry and cell biology from the University of California, San Diego and an MBA from the University of California, Irvine.

Mark Van Oene, Chief Operating Officer

Mark recently joined PacBio in the newly created role of Chief Operating Officer where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities

Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees.

He joined Illumina in 2006 as a regional account manager in Illumina’s sales organization, and advanced rapidly taking on senior commercial leadership roles with ever increasing areas of responsibility, ultimately assuming the Chief Commercial Officer role in 2017. During his fifteen year tenure at Illumina, he was instrumental in scaling Illumina’s global commercial organization, representing the voice of their customers and driving significant annual revenue growth.

Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics.

He earned a BS in Biochemistry from Western University and was a PhD candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.

Jeff Eidel, Chief Commercial Officer

Jeff Eidel joined PacBio as Chief Commercial Officer in August 2022, where he manages all commercial activities including global sales, marketing and customer support.

Jeff brings more than two decades of broad leadership and executive experience to PacBio, most recently holding the role of Chief Executive Officer at Cradle Genomics, a cell-based prenatal testing company in San Diego. Prior to joining Cradle, Jeff was the Head of Corporate & Business Development at Illumina. Jeff joined Illumina in 2006 and held various Commercial, Corporate & Business Development and Finance leadership roles within the company, as well as serving as the General Manager of Illumina’s Madison, Wisconsin site after Illumina’s acquisition of Epicentre Biotechnologies. Jeff held critical positions leading deals with several of the largest NGS customers and business partners, focusing on meeting customer needs, integrating acquisitions, catalyzing global growth, and introducing new products.

Prior to joining Illumina, Jeff worked at KPMG LLP, Corillian Corporation and Inovio Pharmaceuticals in several finance roles.

He earned degrees in Finance and Accounting from the University of Montana.

Susan Kim, Chief Financial Officer

Susan Kim brings more than two decades of senior level finance and operations experience to PacBio. Ms. Kim most recently served as Chief Financial Officer for App Annie and Katerra, both leading venture-backed technology companies. In these roles, she was instrumental in driving revenue growth, scaling finance and operations, and realizing synergies through strategic acquisitions. From 2010 to 2016, Ms. Kim held various leadership roles at KLA Corporation (NASDAQ: KLAC). Prior to KLA, she was an investment banker in Morgan Stanley’s technology practice and started her career as a semiconductor manufacturing engineer for Advanced Micro Devices (NASDAQ: AMD). Ms. Kim earned a BS in Chemical Engineering from Stanford University and an MBA and Master of Engineering Management from Kellogg School of Management, Northwestern University. In 2019, Ms. Kim was recognized as one of the Most Influential Women in Bay Area Business by the San Francisco Business Times.

Michele Farmer, Cpa, Chief Accounting Officer

Michele Farmer joins PacBio from Illumina, where she was the Senior Director of Accounting. She joined Illumina in 2009 and has more than sixteen years of progressive experience in accounting, finance, and auditing roles. Michele most recently led a team responsible for general accounting, consolidation, revenue recognition, mergers and acquisitions, financial systems, financial reporting, and technical accounting. Michele is passionate about building and growing teams to support the company’s strategic goals and objectives. Prior to joining Illumina, Michele started her career as an auditor with PricewaterhouseCoopers. Michele is a Certified Public Accountant and earned her bachelor’s degree in Accounting from San Diego State University.

Jonas Korlach, PhD, Chief Scientific Officer

Jonas Korlach was appointed Chief Scientific Officer of PacBio in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., PacBio Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined PacBio as the company’s eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University.

Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator “Champion of Change.” He received both his PhD and his MS degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received MS and BA degrees in Biological Sciences from Humboldt University in Berlin, Germany.

Stephen Turner, PhD, Chief Technical Officer

Stephen Turner founded PacBio (formerly Nanofluidics) and in 2004 secured its Series A funding. He was awarded a PhD in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. He was a member of the project team at Cornell which developed the technology now employed by PacBio and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. His undergraduate work was at the University of Wisconsin, Madison, where he received a BS in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 50 scientific papers in fields ranging from DNA sequencing technology and biophysics to genomics and epigenomics. He is listed as the inventor on over 50 U.S. patents and numerous published patent applications. He was the recipient of the MIT Technology Review “TR100” Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008.

Natalie Welch, Chief People Officer

Natalie Welch serves as Chief People Officer for PacBio. In her current role, Ms. Welch is responsible for leading PacBio’s overall human resources strategy, global talent management, organizational design, culture and community development. Natalie is a people-focused, results-driven executive with multiple decades of experience in diverse industries and geographies. Natalie joined Pacific Biosciences in 2008 after a 15-year tenure with a hospitality company where she was responsible for people relations, talent planning, and learning and development initiatives. During the last 12 years, she served in various roles of increasing responsibility in Human Resources and Organizational Development for PacBio, building strong relationships to become a trusted partner with leadership, board teams and employees across the company. Now as Chief of People, Natalie is changing the function, culture, and impact of HR across the Company to support its business goals and strategy, as well as the changing dynamics for employees working across the globe. Natalie holds a BS degree in Psychology and post-graduate work in Counseling Psychology from The College of New Jersey.

Corporate Responsibility

ENVIRONMENT

Pacific Biosciences is committed to minimizing the environmental impacts of their business operations and that commitment is embedded in their corporate values. They have an environmental policy to protect their people, environment and the business which is shared with employees during new hire orientation and is tied back to their corporate values. Training and development are provided to minimize risk to their people and the environment and rigorous waste reduction standards that aim to reduce, repurpose, or recycle when possible.

SOCIAL

Pacific Biosciences strives to enable the promise of genomics to better human health and support their customers in their effort to address health disparities by providing an unbiased view of variation across populations. They accelerate their mission every day in the applied use of genomics in areas such as genetic disease, oncology, and sustainable food production. They execute to the highest standards and are proud to maintain rigorous ISO 13485 and ISO 9001 certifications. They hold their large contract manufacturers to similar standards to help ensure they deliver the highest quality services for their advanced sequencing technology.

GOVERNANCE

Pacific Biosciences Board of Directors is composed of leaders with significant experience in building world-class organizations. They bring focus, determination, and a passion for discovery, continually pushing their company to perform at the highest levels. Three of their nine directors are female, one self-identifying as “African American or Black”, as disclosed in their April 14, 2022, Board Diversity Matrix. They have established a cross-functional ESG Core Team made up of leaders in the organization to guide the development and implementation of their ESG strategy. This committee meets monthly and provides quarterly updates to the Corporate Governance and Nominating Committee of the Board of Directors.

Customer insights

“Using PacBio sequencing we can detect mutations that otherwise would be missed in Illumina sequencing” – van Schendel, NAR Genomics and Bioinformatics, 2022

“If your genome isn’t HiFi, it’s no longer reference grade.” — Kevin McKernan, Medicinal Genomics

“What long-read sequencing gives us is the internal nucleotide structure. That’s just unprecedented, and it’s extremely valuable.” — Meredith Course, PhD, Research Fellow University of Washington